Addressing metabolic drivers and counteracting fibrosis

Steatotic liver diseases that are not associated with alcohol consumption are now referred to as metabolic steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH). There is now no need for a liver biopsy to make a diagnosis, which is a great simplification in everyday practice. Treatment is still based on lifestyle modification, but with semaglutide and resmetirome there are two new promising pharmacotherapies, and gastric bypass and gastric sleeve surgery are also evidence-based interventions.